Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF

Newer Version Available: 11264-TC
NEW

Discontinued Product

286-EP has been discontinued and is replaced by 11264-TC.

R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (6)
FAQs
Reviews

Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF Summary

Product Specifications

Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Calibrated against the second international reference preparation of erythropoietin. Annable, L. et al. (1972) Bull. Hlth. Org. 47:99. Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED50 for this effect is 0.02-0.12 units/mL.
Source
Chinese Hamster Ovary cell line, CHO-derived human Erythropoietin/EPO protein
Accession #
Predicted Molecular Mass
21 kDa
SDS-PAGE
37 kDa, reducing conditions

Product Datasheets

You must select a language.

x

286-EP

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

286-EP

Formulation Supplied as a 0.2 μm filtered solution in PBS.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt at -20 to -70 °C as supplied.
  • 1 month at 2-8 °C under sterile conditions after reconstitution.
  • 3 months at -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Erythropoietin/EPO

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin (1). Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species (2, 3). Glycosylation of EPO is required for biological activities in vivo (4). Mature human EPO shares 75%-84% amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules (5). It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain (6-8). EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the EPO receptor (EPO R) (8, 9). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells (7, 8, 10, 11). Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation (1, 12). Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha (1, 6). EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis (7, 8, 13).

References
  1. Koury, M. J. (2005) Exp. Hematol. 33:1263.
  2. Jacobs, K. et al. (1985) Nature 313:806.
  3. Wen, D. et al. (1993) Blood 82:1507.
  4. Tsuda E., et al. (1990) Eur. J. Biochem. 188:405.
  5. Lacombe, C. et al. (1988) J. Clin. Invest. 81:620.
  6. Eckardt, K. U. and A. Kurtz (2005) Eur. J. Clin. Invest. 35: Suppl. 3:13.
  7. Sharples, E. J. et al. (2006) Curr. Opin. Pharmacol. 6:184.
  8. Rossert, J. and K. Eckardt (2005) Nephrol. Dial. Transplant 20:1025.
  9. Koury, M.J. and M.C. Bondurant (1990) Science 248:378.
  10. Acs, G. et al. (2001) Cancer Res. 61:3561.
  11. Hardee, M.E. et al. (2006) Clin. Cancer Res. 12:332.
  12. Verdier, F. et al. (2000) J. Biol. Chem. 275:18375.
  13. Kertesz, N. et al. (2004) Dev. Biol. 276:101.
Entrez Gene IDs
2056 (Human); 13856 (Mouse); 24335 (Rat)
Alternate Names
ECYT5; EP; EPO; epoetin; Erythropoietin; MGC138142; MVCD2

Citations for Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

  1. Discrimination of Dormant and Active Hematopoietic Stem Cells by G0 Marker Reveals Dormancy Regulation by Cytoplasmic Calcium
    Authors: T Fukushima, Y Tanaka, FK Hamey, CH Chang, T Oki, S Asada, Y Hayashi, T Fujino, T Yonezawa, R Takeda, KC Kawabata, T Fukuyama, T Umemoto, K Takubo, H Takizawa, S Goyama, Y Ishihama, H Honda, B Göttgens, T Kitamura
    Cell Rep, 2019-12-17;29(12):4144-4158.e7.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Cell Culture
  2. Erythropoietin Treatment Exacerbates Moderate Injury after Hypoxia-Ischemia in Neonatal Superoxide Dismutase Transgenic Mice
    Authors: RA Sheldon, C Windsor, BS Lee, O Arteaga Ca, DM Ferriero
    Dev. Neurosci., 2017-04-27;0(0):.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  3. Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system
    Gene Ther., 2016-06-30;23(10):699-707.
    Species: Human
    Sample Types: Protein
    Applications: ELISA (Control)
  4. Dynamic interaction networks in a hierarchically organized tissue.
    Authors: Kirouac DC, Ito C, Csaszar E, Roch A, Yu M, Sykes EA, Bader GD, Zandstra PW
    Mol. Syst. Biol., 2010-10-05;6(0):417.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity.
    Authors: Yilmaz OH, Kiel MJ, Morrison SJ
    Blood, 2005-10-11;107(3):924-30.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver.
    Authors: Barcena A, Park SW, Banapour B, Muench MO, Mechetner E
    Blood, 1996-09-15;88(6):2013-25.
    Species: Human
    Sample Types:
    Applications: Bioassay

FAQs

  1. Recombinant Human EPO is listed in units. How does this translate to mass?

    • One unit of Recombinant Human EPO (Ultra Pure; Catalog # 286-EP) or Recombinant Human EPO (Tissue Culture Grade; Catalog # 287-TC) has a mass of approximately 10 ng.

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF and earn rewards!

Have you used Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review